article thumbnail

Decades-long regulatory odyssey ends with FDA nod for Fabre-Kramer's depression med Exxua

Fierce Pharma

Its label doesn't include sexual dysfunction as an adverse reaction, which is rare among antidepressants. Fabre-Kramer Pharmaceuticals' major depressive disorder (MDD) drug gepirone has been rejected by the FDA not once, not twice, but three times since the turn of the millennium.

article thumbnail

STAT+: Experts critique flawed system for monitoring drugs’ side effects in wake of asthma drug report

STAT

and globally, for monitoring adverse reactions after a drug is on the market — one that will require extensive changes to address. Experts say that the Singulair incident highlights a flawed system, both in the U.S.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

FDA Proposes Streamlined Medication Handouts

PharmExec

New program seeks to reduce misuse and adverse reactions by simplifying prescription labels.

article thumbnail

First-in-class phosphate absorption inhibitor approved by FDA

European Pharmaceutical Review

However, in the trials, the only observed adverse reaction for the treatment was diarrhoea. Most XPHOZAH-treated patients experienced mild-to-moderate reactions that resolved over time, or with dose reduction. XPHOZAH is expected to be available to eligible patients in the US in November 2023.

FDA 114
article thumbnail

US FDA approves Blueprint Medicines’ indolent systemic mastocytosis therapy

Pharmaceutical Technology

With a broad indication for indolent systemic mastocytosis and a strong label, we are now engaging healthcare providers to redefine what it means for their patients to be well-controlled, as well as activating the patient community to seek out optimal care and treatment.”

FDA 98
article thumbnail

Japan’s MHLW approves Daiichi Sankyo’s breast cancer treatment

Pharmaceutical Technology

The latest development was based on the findings from the international, head-to-head, open-label, randomised Phase III DESTINY-Breast03 trial which analysed the efficacy and safety of Enhertu versus trastuzumab emtansine (T-DM1).

article thumbnail

First paediatric EC approval of HIV drug

European Pharmaceutical Review

The extension authorisation is based on an ongoing open-label, 24-week study ( NCT02881320 ), which indicated Biktarvy ® was effective and generally well-tolerated by virologically suppressed adolescents and children with HIV. After Week 48, participants could receive Biktarvy ® in an active open-label extension phase for up to 96 weeks.